Connecticut, US-based pharmaceutical firm Mederi Therapeutics raised $18.5 million in a Series B funding round for the sales and marketing of its treatment for Gastrointestinal Reflux Disease (GERD) and fecal incontinence.
Medical Device and Diagnostic Industry
Breaking News
Subscribe to VCpost newsletter
Most Popular
- 940,000 Taxpayers May Receive Extra $932 Tax Refunds From IRS; Here's Why!
- China Hits 2 U.S. Defense Companies With Sanctions For Selling Military Weapons to Taiwan
- American Airlines Pilots Union Issues Urgent Safety Alert Over Maintenance Issues
- Innocent Female Uber Driver, 61, Shot Dead by 81-Year-Old Ohio Man Who Was Targeted by Scammers
- Trump Media’s First Auditor Quits After Just a Few Months on the Job: Report
- Proposed Chinese Train Station Garners Attention Online as It Looks Like Sanitary Pad
- Google Starts Removing Links to California News Websites in Response to Journalism Preservation Act
- Spirit Airlines Staff at Florida Airport Filmed Cursing a 'Karen' Passenger After Moaning About Her Flight
